Dr. Ahmad Trad completed his PhD (2009) in immunology, in the laboratory of Dr. Hilmar Lemke, after having earned his B.Sc. (2002) in Biochemistry at the Lebanese University, Lebanon, and his M.Sc. (2005) in Biochemistry at the Christian-Albrechts-University of Kiel, Germany.
Dr. Trad has generated monoclonal antibodies using hybridoma technology in transgenic animals harboring single Dh gene and worked in the laboratory of Dr. Joachim Grötzinger at the University of Kiel where he focused on the use of anti-ADAM17 monoclonal antibodies to target tumor cells. In addition, Dr. Trad served as head of the monoclonal antibody core facility, generating monoclonal antibodies against different antigens and validated them for different immune assays. In 2014, he joined Abcheck S.r.o. as Head of Cell Culture, supporting the therapeutic antibody discovery, and establishing novel cell-based assays. Since 2022 he is the Head of Antibody Lab at betaSENSE, leading a team responsible for discovery of new monoclonal antibodies against biomarker proteins of neurodegenerative diseases. Furthermore, he is developing a site-selective orientated immobilization of antibody and antibody’s fragments to an Immuno-Infrared Sensor.